C/EBPβ Expression in ALK-positive Anaplastic Large Cell Lymphomas is Required for Cell Proliferation and is Induced by the STAT3 Signaling Pathway

Overview

Journal Haematologica

Specialty Hematology

Date 2009 Dec 18

PMID 20015877

Citations 32

Authors

Natasa Anastasov

Irina Bonzheim

Martina Rudelius

Margit Klier

Therese Dau

Daniela Angermeier

Justus Duyster

Stefania Pittaluga

Falko Fend

Mark Raffeld

Leticia Quintanilla-Martinez

Affiliations

Soon will be listed here.

Abstract

Background: Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma is characterized by the t(2;5) chromosomal translocation, resulting in the expression of a fusion protein formed of nucleophosmin (NPM) and ALK. Recently, we reported the abnormal expression of the transcription factor CCAAT/enhancer binding protein-beta (C/EBPbeta) in ALK-positive anaplastic large cell lymphomas, and demonstrated its dependence on NPM-ALK activity.

Design And Methods: In this study, the role of C/EBPbeta in proliferation and survival of ALK-positive anaplastic large cell lymphomas was investigated, as well as the mechanism of its expression and activity. Highly effective short hairpin RNA sequences and/or pharmacological inhibitors were used to abrogate the expression or activity of C/EBPbeta, signal transducer and activator of transcription 3 (STAT3), AKT, extracellular signal-related kinase 1/2 (ERK1/2) and mammalian target of rapamycin (mTOR).

Results: Interference with C/EBPbeta expression resulted in a dramatic decrease in cell proliferation in ALK-positive anaplastic large cell lymphomas, with a mild induction of apoptosis after 6 days. Down-regulation of STAT3 resulted in a marked decrease in C/EBPbeta mRNA and protein levels with impairment in cell proliferation and viability, underscoring the important role of these two proteins in ALK-mediated oncogenesis. Additionally, we demonstrated that reduction of ERK1/2 activity led to C/EBPbeta Thr(235) dephosphorylation and moderate growth retardation. The AKT/mTOR signaling pathway did not have any influence on C/EBPbeta expression or C/EBPbeta phosphorylation.

Conclusions: These findings reveal the convergence of STAT3 and ERK1/2 signaling pathways activated by NPM-ALK in mediating the regulation of C/EBPbeta expression, a transcription factor central to NPM-ALK transformation.

Citing Articles

Updates in pathobiological aspects of anaplastic large cell lymphoma.

Wu R, Lim M Front Oncol. 2023; 13:1241532.

PMID: 37810974 PMC: 10556522. DOI: 10.3389/fonc.2023.1241532.

CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.

Montes-Mojarro I, Steinhilber J, Griessinger C, Rau A, Gersmann A, Kohlhofer U Leukemia. 2022; 36(8):2050-2063.

PMID: 35676454 PMC: 9343252. DOI: 10.1038/s41375-022-01617-x.

Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.

Schmidt T, Klempnauer K Molecules. 2022; 27(7).

PMID: 35408476 PMC: 9000602. DOI: 10.3390/molecules27072077.

Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment.

Zhang X, Chien P, Nam S, Heo C Cancers (Basel). 2022; 14(7).

PMID: 35406421 PMC: 8997054. DOI: 10.3390/cancers14071650.

C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.

Yusenko M, Trentmann A, Casolari D, Abdel Ghani L, Lenz M, Horn M Oncogene. 2021; 40(29):4746-4758.

PMID: 33958723 PMC: 8298201. DOI: 10.1038/s41388-021-01800-x.

References

Lamant L, De Reynies A, Duplantier M, Rickman D, Sabourdy F, Giuriato S . Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood. 2006; 109(5):2156-64. DOI: 10.1182/blood-2006-06-028969. View

Rask K, Thorn M, Ponten F, Kraaz W, Sundfeldt K, Hedin L . Increased expression of the transcription factors CCAAT-enhancer binding protein-beta (C/EBBeta) and C/EBzeta (CHOP) correlate with invasiveness of human colorectal cancer. Int J Cancer. 2000; 86(3):337-43. DOI: 10.1002/(sici)1097-0215(20000501)86:3<337::aid-ijc6>3.0.co;2-3. View

Piwien-Pilipuk G, MacDougald O, Schwartz J . Dual regulation of phosphorylation and dephosphorylation of C/EBPbeta modulate its transcriptional activation and DNA binding in response to growth hormone. J Biol Chem. 2002; 277(46):44557-65. DOI: 10.1074/jbc.M206886200. View

Piwien-Pilipuk G, Van Mater D, Ross S, MacDougald O, Schwartz J . Growth hormone regulates phosphorylation and function of CCAAT/enhancer-binding protein beta by modulating Akt and glycogen synthase kinase-3. J Biol Chem. 2001; 276(22):19664-71. DOI: 10.1074/jbc.M010193200. View

Specht K, Kremer M, Muller U, Dirnhofer S, Rosemann M, Hofler H . Identification of cyclin D1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections. Clin Cancer Res. 2002; 8(9):2902-11. View

Marzec M, Kasprzycka M, Liu X, Raghunath P, Wlodarski P, Wasik M . Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene. 2006; 26(6):813-21. DOI: 10.1038/sj.onc.1209843. View

IWAHARA T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T . Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene. 1997; 14(4):439-49. DOI: 10.1038/sj.onc.1200849. View

Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F . Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest. 2006; 116(12):3171-82. PMC: 1636692. DOI: 10.1172/JCI29401. View

Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath P . Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Oncogene. 2007; 26(38):5606-14. DOI: 10.1038/sj.onc.1210346. View

10.

Bai R, Dieter P, Peschel C, Morris S, Duyster J . Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol. 1998; 18(12):6951-61. PMC: 109278. DOI: 10.1128/MCB.18.12.6951. View

11.

Duyster J, Bai R, Morris S . Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001; 20(40):5623-37. DOI: 10.1038/sj.onc.1204594. View

12.

Piwien Pilipuk G, Galigniana M, Schwartz J . Subnuclear localization of C/EBP beta is regulated by growth hormone and dependent on MAPK. J Biol Chem. 2003; 278(37):35668-77. DOI: 10.1074/jbc.M305182200. View

13.

Anastasov N, Klier M, Koch I, Angermeier D, Hofler H, Fend F . Efficient shRNA delivery into B and T lymphoma cells using lentiviral vector-mediated transfer. J Hematop. 2009; 2(1):9-19. PMC: 2713496. DOI: 10.1007/s12308-008-0020-x. View

14.

Tenen D . Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer. 2003; 3(2):89-101. DOI: 10.1038/nrc989. View

15.

Lois C, Hong E, Pease S, Brown E, Baltimore D . Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science. 2002; 295(5556):868-72. DOI: 10.1126/science.1067081. View

16.

Descombes P, Schibler U . A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell. 1991; 67(3):569-79. DOI: 10.1016/0092-8674(91)90531-3. View

17.

Sundfeldt K, Ivarsson K, Carlsson M, Enerback S, Janson P, Brannstrom M . The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression. Br J Cancer. 1999; 79(7-8):1240-8. PMC: 2362217. DOI: 10.1038/sj.bjc.6690199. View

18.

Gao L, Xu D, Wen L, Zhang X, Shao Y, Zhao X . Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol Sin. 2005; 26(3):377-83. DOI: 10.1111/j.1745-7254.2005.00053.x. View

19.

Tanaka N, Hoshino Y, Gold J, Hoshino S, Martiniuk F, Kurata T . Interleukin-10 induces inhibitory C/EBPbeta through STAT-3 and represses HIV-1 transcription in macrophages. Am J Respir Cell Mol Biol. 2005; 33(4):406-11. PMC: 2715348. DOI: 10.1165/rcmb.2005-0140OC. View

20.

Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G . The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2007; 8(1):11-23. DOI: 10.1038/nrc2291. View